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ABSTRACT
In bone marrow, osteoblasts and adipocytes are differenti-
ated from mesenchymal progenitor cells and their differ-
entiation is reciprocally regulated by largely unknown
mechanisms. In this study, we investigated downstream
signaling cascades of adiponectin, a member of the adipo-
cytokine family, in the regulation of osteoblast differentia-
tion. Adiponectin augmented expression of several
osteogenic marker genes and increased osteoblast differen-
tiation in mesenchymal progenitor cells. The expression of
cyclooxygenase-2 (COX2) was potently increased by adipo-
nectin, whereas inhibition of COX2 activity abolished the
effect of adiponectin on osteogenesis. In addition, adipo-
nectin rapidly stimulated p38 mitogen-activated protein ki-
nase via the adiponectin receptor, AdipoR1, which
resulted in c-Jun activation for COX2 expression. Adipo-
nectin also stimulated BMP2 expression in a COX2-de-
pendent manner. Moreover, Runx2, a key osteogenic
transcription factor, contributed to the acceleration of
osteogenesis in the presence of adiponectin. Collectively,
the ﬁnding that adiponectin could promote osteogenesis
through an intracellular signaling cascade in mesenchymal
progenitor cells suggests that adiponectin would be a
potential therapeutic target for bone-related diseases.
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INTRODUCTION
In bone marrow, common marrow mesenchymal progenitor
cells are able to differentiate into several cell types such as
adipocytes and osteoblasts [1]. Recent evidence suggests that
there is an inverse correlation between adipocyte differentia-
tion and osteoblast differentiation from common progenitor
cells [2, 3]. An increase in adiposity due to elevated adipo-
genesis in bone marrow, which is caused by aging, obesity,
and diabetes, is one of the major risk factors of bone-related
disorders, including osteoporosis and bone fractures [4–7].
Although the precise mechanism is not thoroughly under-
stood, adipocytokines released from adipocytes, including lep-
tin, resistin, and adiponectin, are associated with the regula-
tion of bone mineral density [8]. For example, leptin-deﬁcient
mice exhibit increased bone mass, whereas intracerebroven-
tricular infusion of leptin causes bone loss [9]. However, the
roles of other adipocytokines in bone metabolism are largely
unknown.
Adiponectin (also known as Acrp30, AdipoQ, apM1, and
GBP28) is an adipocytokine exclusively expressed from adi-
pocytes [10]. Adiponectin dysregulation has been implicated
in insulin resistance, diabetes, and cardiovascular diseases
[11]. One of the most interesting features of adiponectin is
that its expression level in adipose tissue and plasma is
decreased in obese and diabetic subjects, who have larger fat
cells, showing dysregulated energy homeostasis [12]. Several
adiponectin receptors or binding molecules, such as AdipoR1,
AdipoR2, T-cadherin, and calreticulin, have been reported
[10, 13]. Among these, AdipoR1 is ubiquitously expressed—
and highly expressed in skeletal muscle—whereas AdipoR2 is
abundantly expressed in the liver [10]. AdipoR1- and Adi-
poR2-mediated adiponectin stimulate glucose uptake and fatty
acid oxidation through the activation of AMPK (AMP-acti-
vated protein kinase) and p38 mitogen-activated protein ki-
nase (MAPK), which results in increased insulin sensitivity
[14, 15]. Although adiponectin stimulates osteoblast prolifera-
tion and differentiation via AdipoR1 [16], the downstream
signaling cascades of adiponectin during osteogenesis are not
thoroughly understood.
Prostaglandin E2 (PGE2), which is produced by cyclooxy-
genase-2 (COX2) in osteoblasts, plays critical roles in bone
anabolism [17]. The elevation of PGE2 by systemic or local
infection stimulates bone formation, and increased lamellar
bone formation in response to mechanical stress is mediated
by COX2 [18–20]. In addition, COX2 knockout mice exhibit
decreased mesenchymal progenitor cell differentiation into
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osteoblast lineage when compared with wild-type littermates
[21]. Thus, it is likely that regulatory molecules for COX2
expression in osteogenic cells would result in changes in bone
metabolism.
Recently, it has been reported that adiponectin is expressed
in bone marrow cells and is present in bone marrow regions [1,
22]. In addition, adiponectin represses adipogenesis in bone
marrow progenitor cells [23]. These ﬁndings led us to test
whether adiponectin can affect osteogenesis in mesenchymal
progenitor cells. In this study, we demonstrate that adiponectin
stimulates osteoblast differentiation in a COX2-dependent man-
ner. During adiponectin-mediated osteogenesis in mesenchymal
progenitor cells, AdipoR1 and p38 MAPK are activated to pro-
mote the phosphorylation of c-Jun, which is an essential step in
turning on osteoblast differentiation via COX2 expression. Col-
lectively, these data suggest that adiponectin could be a positive
inducer of osteogenesis in mesenchymal progenitor cells.
MATERIALS AND METHODS
Cell Culture and Differentiation of Osteoblasts
C3H10T1/2 murine mesenchymal progenitor cells were main-
tained in Dulbecco’s modiﬁed Eagle’s medium (DMEM; Gibco-
BRL, Gaithersburg, MD, http://www.gibcobrl.com) supplemented
with 10% fetal bovine serum (FBS). Osteoblast differentiation
was induced with DMEM containing 10% FBS, 50 lM ascorbic
acid, and 10 mM b-glycerophosphate. Primary bone marrow cells
(PBMCs) were isolated from the femur and tibia of 4-week-old
C57BL/6J mice and maintained in a-modiﬁed essential medium
(a-MEM; Gibco BRL) with 10% FBS and 100 nM hydrocor-
tisone. For osteoblast differentiation, PBMCs were cultured in
a-MEM with 10% FBS, 50 lM ascorbic acid, and 10 mM
b-glycerophosphate.
Puriﬁcation of Adiponectin from HEK293
Cell Cultures
Recombinant adiponectin protein was puriﬁed using a previously
described protocol [15]. The purity and oligomerization of adipo-
nectin were examined before use.
siRNA Transfection
For transient transfection, C3H10T1/2 cells were grown to 80%
conﬂuence and subsequently transfected with several siRNA
(small interference-RNA) using a MicroPorator according to the
manufacturer’s instructions (pipette-type electroporator; INCYTO
Co., Ltd., Cheonan-city, Koreahttp://www.incyto.com). To mini-
mize the possibility of different transfection efﬁciencies, siRNA-
transfected C3H10T1/2 cells were split and treated with or with-
out adiponectin. The siRNA duplexes for AdipoR1, c-Jun, and
Runx2 that contained the most efﬁcient capacity recommended
by Bioneer were purchased from them (Bioneer, Daejeon, Korea,
http://www.bioneer.com). The siRNA sets used were as follows:
AdipoR1 forward, 50-GAC UUG GCU UGA GUG GUG U
(dTdT)-30; c-Jun forward, 50-GAG AAG AGG AAC CUA UAC
U (dTdT)-30; Runx2 forward, 50-CGA UCU GAG AUU UGU
GGG C (dTdT)-30.
Transient Transfection, DNA Constructs, and
Reporter Assay
For luciferase assays, we transiently transfected pCS4-3 Myc-
Runx2 and pII1.3-Luc (1.3 kilobases of osteocalcin promoter) in
HEK293 cells using the calcium phosphate method. C3H10T1/2
cells were transiently transfected with pXP-2-COX2-Luc using a
MicroPorator. At 12 hours after transfection, adiponectin (10 lg/
ml) treated for 12 hours and cell lysates were analyzed for lucif-
erase activity. The pCMV-b-galactosidase plasmid and green ﬂu-
orescent protein expression plasmid were used as internal controls
for transfection efﬁciency.
Western Blotting
Western blotting was performed as previously described [24].
Antibodies against COX2 (NeoMarkers, USA), p38 MAPK,
FLAG, phosphorylated c-Jun (serine 63 residue), and c-Jun (Santa
Cruz Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com),
b-actin (Sigma-Aldrich, St. Louis, http://www.sigmaaldrich.com),
GAPDH (AbFrontier, Seoul, Korea, http://www.abfrontier.com),
and phosphorylated p38 MAPK (BD Biosciences, San Diego,
http://www.bdbiosciences.com) were used. Western blot analyses
were visualized with horseradish peroxidase-conjugated secondary
antibodies (Sigma-Aldrich) and enhanced chemiluminescence.
Real-Time Quantitative Polymerase Chain Reaction
Total RNA was isolated with Trizol reagent (Invitrogen, Carls-
bad, CA, http://www.invitrogen.com) according to the manufac-
turer’s protocol. After isolation of total RNA, the complementary
DNA was generated by M-MuLV reverse transcriptase (Fermentas
Canada Inc., Burlington, Ontario, Canada, http://www.fermentas.
com) and was analyzed by quantitative real-time polymerase chain
reaction (qPCR; My-IQ thermocycle; Bio-Rad, Hercules, CA,
http://www.bio-rad.com) with SYBR Green (BioWhittaker Molecu-
lar Application, Rockland, ME, http://www.biowhittaker.com). All
reaction products were normalized to the expression level of
mRNA. PCR primer sets used were as follows: AdipoR1 forward,
50-ACG TTG GAG AGT CAT CCC GTA T-30; reverse, 50-CTC
TGT GTG GAT GCG GAA GAT-30; AdipoR2 forward, 50-TAG
CCT CTA TAT CAC CGG AGC T-30; reverse, 50-AGA AGG CCT
GCA GGA CCT GCA-30; ALP forward, 50-GAC TGG TAC TCG
GAT AAC GA-30; reverse, 50-TGC GGT TCC AGA CAT AGT
GG-30; BMP2 forward, 50-TGG AAG TGG CCC ATT TAG AG-30;
reverse, 50-TGA CGC TTT TCT CGT TTG TG-30; BMP7 forward,
50-GAA AAC AGC AGC AGT GAC CA-30; reverse, 50-GGT GGC
GTT CAT GTA GGA GT-30; c-Jun forward, 50-TCC CCT ATC
GAC ATG GAG TC-30; reverse, 50-TGA GTT GGC ACC CAC
TGT TA-30; COX2 forward, 50-AGA AGG AAA TGG CTG CAG
AA-30; reverse, 50-GCT CGG CTT CCA GTA TTG AG-30;
GAPDH forward, 50-TGC ACC ACC AAC TGC TTA G-30;
reverse, 50-GGA TGC AGG GAT GAT GTT C-30; osteocalcin for-
ward, 50-CGC TCT CAG GGG CAG ACA CT-30; reverse, 50-GCA
CCC TCC AGC ATC CAG TA-30; osteopontin forward, 50-TGC
CTG ACC CAT CTC AGA AGC A-30; reverse, 50-TGA GAG GTG
AGG TCC TCA TC-30; Runx2 forward, 50-GAA GGA AAG GGA
GGA GGG GT-30; reverse, 50-TCT GTC TCT CCT TCC CTT CC-
30; 18S forward, 50-ACC GCA GCT AGG AAT AAT GGA-30;
reverse, 50-GCC TCA GTT CCG AAA ACC A-30.
p38 Mitogen-Activated Protein Kinase In Vitro
Kinase Assay
HEK293 cells transfected with FLAG-p38 MAPK were lysed on
ice using TGN buffer. The total cell extract (500 lg) was immu-
noprecipitated with anti-FLAG antibodies and washed with
20 mM HEPES (pH 7.4). Kinase assays were performed for
30 minutes at 30C using 2 lg of glutathione S-transferase-c-Jun
(GST-c-Jun) as the substrate in the reaction buffer (20 mM
HEPES [pH 7.4], 10 mM MgCl2, 12 mM b-glycerophosphate,
1 mM Na3VO4, 2 mM dithiothreitol, 0.5 mM phenylmethylsulfo-
nyl ﬂuoride, and 1 lCi [c-32P] ATP). The reactions were termi-
nated using 5 SDS sample buffer. The products were then
resolved by SDS-PAGE, and the level of incorporated [32P] was
detected by autoradiography. Following this, the membranes were
immunoblotted using anti-FLAG antibodies.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assays were performed as
described previously [24]. The PCR primer sets used in this study
were as follows: COX2 promoter forward, 50-AGC TGT GTG
CGT GCT CTG A-30; reverse, 50-TCG CAG TTT GAC AAC
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TGG C-30; osteocalcin promoter forward, 50-CGC TCT CAG
GGG CAG ACA CT-30; reverse, 50-GCA CCC TCC AGC ATC
CAG TA-30; osteopontin promoter forward, 50-GGC CAA CCT
AAG CTA CCG AA-30; reverse, 50-CCA CCA ATC AGG AGG
TGG AG-30.
Enzyme Immunoassay for PGE2
C3H10T1/2 cells in 12-well plates were incubated in 1 ml of
medium with or without adiponectin. Supernatants from these
cultures were examined for the presence of PGE2 using an
enzyme immunoassay kit (Cayman Chemical, Ann Arbor, MI,
http://www.caymanchem.com).
Alkaline Phosphatase Staining
Differentiated osteoblast cells were stained for alkaline phospha-
tase (ALP) activity using the 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium (BCIP/NBT) color development sub-
strate (Promega, Madison, WI, http://www.promega.com).
Statistics
Data were analyzed using Student’s t test. p < .05 and p < .01
were considered signiﬁcant.
RESULTS
Adiponectin Stimulates Osteogenesis in
Mesenchymal Progenitor Cells
To investigate the effect of adiponectin on osteogenesis of
mesenchymal progenitor cells, the mesenchymal progenitor
cell line C3H10T1/2 and mouse PBMCs were treated with or
without adiponectin during osteogenic differentiation. As
shown in Figure 1A, adiponectin increased ALP-positive cells
in both cell types. Consistently, the expression of osteogenic
marker genes, including type I collagen, osteopontin, osteocal-
cin, and ALP, were stimulated by adiponectin (Fig. 1B). Fur-
thermore, adiponectin overexpression via adenovirus also
increased the expression of osteogenic genes such as osterix
and osteopontin during osteogenesis (supporting information
Fig. S1). In C3H10T1/2 cells, the expression level of osteo-
pontin and osteocalcin was signiﬁcantly increased at the early
stage of osteogenic differentiation (day 2) with adiponectin
(Fig. 1C). Similarly, the levels of ALP-positive cells and cal-
cium deposition were greatly increased by adiponectin in
PBMCs (supporting information Fig. S2). These results imply
that adiponectin might promote osteogenesis at the early stage
of osteoblast differentiation in mesenchymal progenitor cells.
Adiponectin Promotes COX2 Expression in
Mesenchymal Progenitor Cells
To investigate the effect of adiponectin on the expression of
other osteogenic genes, we analyzed the mRNA levels of
Runx2 and COX2 together with osteocalcin and osteopontin.
In accordance with the above results, the expression of most
osteogenic genes, but not Runx2, was elevated by adiponectin
(Fig. 2A). Of these, adiponectin rapidly increased both
mRNA and protein levels of COX2 within 3 hours of treat-
ment in C3H10T1/2 cells (Fig. 2A, 2B). Increases in COX2
expression by adiponectin were also monitored in PBMCs,
preosteoblastic MC3T3-E1 cells (supporting information Fig.
S3A, S3B). Previously, it was shown that COX2 plays a role
in producing osteogenic stimulator PGE2 in osteogenesis [17,
21]. At the same time, the level of PGE2, the product of
COX2, was increased by adiponectin in C3H10T1/2 cells
(Fig. 2C) and PBMCs (supporting information Fig. S3C).
However, COX2 expression was not altered in other adipo-
nectin-sensitive cells, such as FAO hepatocytes and differ-
entiated C2C12 myocytes, whereas the expression of Acyl-
CoA oxidase, a well-known adiponectin target gene, was
induced by adiponectin in those cells (supporting information
Fig. S4). This indicated that adiponectin would increase
COX2 expression speciﬁcally in mesenchymal progenitor
cells and preosteoblastic cells.
To determine the role of COX2 induction by adiponectin
for osteogenesis, we examined the effects of COX2 inhibitors
on adiponectin-induced osteogenesis. In C3H10T1/2 cells,
increased expression of osteopontin, osteocalcin, and COX2
by adiponectin was signiﬁcantly reduced by the COX2-
speciﬁc inhibitor, NS398, during osteoblast differentiation
(Fig. 2D). Additionally, in PBMCs, ALP-positive cells ele-
vated by adiponectin were decreased by another COX2 inhibi-
tor, salicylate, whereas PGE2 reversed the effect of salicylate
on osteogenesis, as determined by ALP staining assay (sup-
porting information Fig. S5). Taken together, these results
suggest that increased COX2 expression is crucial for adipo-
nectin-mediated stimulation of osteogenesis in mesenchymal
progenitor cells.
Figure 1. Adiponectin stimulates osteogenesis in mesenchymal pro-
genitor cells. (A): C3H10T1/2 cells and primary bone marrow cells
were differentiated into osteoblasts in the presence or absence of adi-
ponectin (10 lg/ml) for 6 and 9 days, respectively. Differentiated
osteoblasts were monitored by ALP staining to reveal ALP-positive
cells. (B): C3H10T1/2 cells were differentiated into osteoblasts with
or without adiponectin (10 lg/ml) for 6 days. Relative levels of osteo-
pontin, osteocalcin, type 1 collagen, and ALP mRNA were deter-
mined using real-time quantitative polymerase chain reaction (qPCR).
Values are normalized to the levels of GAPDH mRNA. (C):
C3H10T1/2 cells were differentiated into osteoblasts with or without
adiponectin (10 lg/ml). Cells were harvested at the indicated times.
Relative levels of osteopontin and osteocalcin mRNA were deter-
mined using real-time qPCR. Values are normalized to the levels of
GAPDH mRNA. Values are expressed as the mean  SD. *, p < .05;
**, p < .01. Abbreviations: ALP, alkaline phosphatase; APN, adipo-
nectin; OCN, osteocalcin; OPN, osteopontin; PBMCs, primary bone
marrow cells.
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Induction of COX2 Expression by Adiponectin Is
Dependent on c-Jun
Next, we investigated the molecular mechanism by which adi-
ponectin could induce COX2 expression in mesenchymal pro-
genitor cells. As illustrated in Figure 3A, the transcriptional
activity of the COX2 promoter was increased by adiponectin
in reporter assays with C3H10T1/2 cells. Because the COX2
promoter is tightly regulated by AP-1 factors [25], especially
c-Jun, we investigated the mRNA levels of c-Jun following
adiponectin treatment. Adiponectin rapidly (approximately
3 hours) promoted c-Jun mRNA production (Fig. 3B). Next,
we performed ChIP assays to decipher whether c-Jun is
indeed involved in the augmentation of COX2 expression by
adiponectin. Adiponectin signiﬁcantly increased c-Jun recruit-
ment onto the promoter of the COX2 gene (Fig. 3C). More-
over, recruitment of p300, a well-known coactivator for c-Jun
[26], onto the COX2 promoter was also increased by adipo-
nectin treatment (Fig. 3C). To investigate the role of c-Jun in
COX2 expression with adiponectin, we repressed endogenous
c-Jun expression via siRNA. In C3H10T1/2 cells, increased
COX2 protein by adiponectin was markedly reduced by c-Jun
knockdown (Fig. 3D). Thus, these results strongly suggest
that c-Jun plays an important role in the increase of COX2
expression upon adiponectin in mesenchymal progenitor cells.
p38 MAPK Phosphorylates c-Jun by Adiponectin
Because the phosphorylation of c-Jun is important to its pro-
tein stability and transcriptional activity [27], we investigated
the phosphorylation status of c-Jun with or without adiponec-
tin. In C3H10T1/2 cells, c-Jun phosphorylation was signiﬁ-
cantly increased by adiponectin within short (<15 minutes)
periods (Fig. 4A). Furthermore, phosphorylation of p38
MAPK, a c-Jun upstream kinase [28], was also increased by
adiponectin (Fig. 4A). Although the meaning of the biphasic
increase in p38 MAPK phosphorylation is still unclear, bipha-
sic p38 MAPK phosphorylation by adiponectin was repeatedly
detected. Similarly, phosphorylation of p38 MAPK by adipo-
nectin was increased in PBMCs (supporting information Fig.
S6A). To examine whether p38 MAPK directly phosphoryl-
ates c-Jun upon exposure to adiponectin, we performed in
vitro kinase assays using GST-c-Jun proteins. As shown in
Figure 4B, phosphorylation of GST-c-Jun protein by p38
MAPK was augmented by adiponectin. In addition, a speciﬁc
inhibitor for p38 MAPK, SB203580, greatly inhibited c-Jun
phosphorylation (Fig. 4C) and signiﬁcantly repressed the
Figure 2. Adiponectin promotes osteogenesis via COX2 induction.
(A–C): Adiponectin (10 lg/ml) was treated for the indicated time peri-
ods in C3H10T1/2 cells. (A): Relative amounts of COX2, osteopontin,
osteocalcin, and Runx2 mRNA were determined using real-time quan-
titative polymerase chain reaction (qPCR). Values are normalized to
the levels of GAPDH mRNA. (B): Western blot analyses were con-
ducted using antibodies against COX2 (a-COX2) and b-actin (a-b-
actin). Antibodies against b-actin (a-b-actin) were used as the loading
control. (C): The concentration of PGE2 was determined using the
PGE2 EIA kit (Cayman Chemical). (D): Adiponectin (10 lg/ml) and
NS398 (10 lM), which is a COX2-speciﬁc inhibitor, were added to
C3H10T1/2 cells until differentiation, day 5. Relative levels of each
mRNA were determined using real-time qPCR. Values are normalized
to the levels of GAPDH mRNA. Values are expressed as the mean 
SD. *, p < .05; **, p < .01. Abbreviations: APN, adiponectin; COX2,
cyclooxygenase-2; OCN, osteocalcin; OPN, osteopontin; PGE2, prosta-
glandin E2; Runx2, Runt-related transcription factor 2.
Figure 3. c-Jun mediates COX2 expression by adiponectin. (A): A
reporter construct containing the COX2 promoter was transfected in
C3H10T1/2 cells with and without adiponectin (10 lg/ml). Luciferase
activities were determined 12 hours after adiponectin treatment. Trans-
fection efﬁciency was normalized with green ﬂuorescent protein. (B):
Adiponectin (10 lg/ml) was treated for the indicated time periods in
C3H10T1/2 cells. Relative amounts of c-Jun mRNA were determined
using real-time quantitative polymerase chain reaction. Values are nor-
malized to the levels of GAPDH mRNA. (C): C3H10T1/2 cells were
treated with adiponectin (10 lg/ml) for 3 hours. Chromatin immuno-
precipitation assays were performed to monitor the recruitment of
c-Jun and its coactivator, p300, onto the COX2 promoter. The input
represents 10% of the total input chromatin. (D): C3H10T1/2 cells
were transfected with scrambled or c-Jun siRNA and treated with and
without adiponectin (10 lg/ml) for 3 hours. Western blot analyses
were conducted using antibodies against COX2 (a-COX2), phospho-
rylated c-Jun (a-p-c-Jun), c-Jun (a-c-Jun), and GAPDH (a-GAPDH).
Antibodies against GAPDH (a-GAPDH) were used as the loading con-
trol. Values are expressed as the mean  SD. *, p < .05; **, p < .01.
Abbreviations: APN, adiponectin; ChIP, chromatin immunoprecipita-
tion; COX2, cyclooxygenase-2.
Lee, Kim, Kim et al. 2257
www.StemCells.com
levels of COX2 protein and mRNA in C3H10T1/2 cells (Fig.
4C, 4D). The p38 MAPK inhibitor consistently suppressed
adiponectin-induced PGE2 levels and COX2 expression in
PBMCs (supporting information Fig. S6B, S6C). Because adi-
ponectin promoted both c-Jun mRNA and protein levels, and
also c-Jun phosphorylation (Figs. 3B, 4A), we questioned
whether adiponectin-dependent COX2 expression is primarily
associated with an increase in c-Jun expression or c-Jun pro-
tein phosphorylation. To address this, cycloheximide was
treated with adiponectin to inhibit de novo synthesis of c-Jun
protein. In the presence of cycloheximide, COX2 mRNA
expression was greatly increased by adiponectin, although the
p38 MAPK inhibitor still repressed the expression of COX2
mRNA (Fig. 4E), implying that an increase in c-Jun phospho-
rylation by adiponectin via p38 MAPK would be an important
prerequisite step to induce COX2 expression. Accordingly,
elevated expression of several osteogenic genes, including
COX2, osteopontin, and osteocalcin, by adiponectin was
greatly prevented by SB203580 during osteogenic differentia-
tion (Fig. 4F). SB203580 also lessened adiponectin-induced
ALP-positive staining in PBMCs and MC3T3-E1 cells (sup-
porting information Fig. S6D). Taken together, these results
propose that p38 MAPK would increase c-Jun phosphoryla-
tion by adiponectin, which would lead to enhanced COX2
expression in mesenchymal progenitor cells.
Adiponectin Activates BMP2 Expression via COX2
in C3H10T1/2 Cells
BMP2 is one of the most important growth factors that stimu-
lates osteogenesis and osteogenic marker genes like osteopon-
tin and osteocalcin [29]. Because endogenous PGE2 regulates
BMP2 expression in human mesenchymal progenitor cells
[30], we investigated whether adiponectin is able to control
BMP expression through COX2 induction. As illustrated in
Figure 5A, adiponectin greatly increased expression of BMP2,
but not BMP7, in C3H10T1/2 cells. Then, to study whether
elevation of PGE2 by adiponectin was involved in the regula-
tion of BMP2 expression, C3H10T1/2 cells were co-treated
with adiponectin and the COX2 inhibitor NS398. As shown
Figure 4. Adiponectin increases c-Jun phosphorylation and COX2 expression via p38 MAPK. (A): Adiponectin (10 lg/ml) was treated for the
indicated time periods in C3H101/2 cells. The phosphorylation and protein levels of c-Jun and p38 MAPK were monitored by Western blot anal-
yses. Antibodies against b-actin (a-b-actin) were used as the loading control. (B): p38 MAPK kinase activity was determined in the absence or
presence of adiponectin. HEK293 cells were transfected with FLAG-p38 MAPK and treated with adiponectin for the indicated time periods.
Whole cell lysates were immunoprecipitated with anti-FLAG antibodies (a-FLAG), and in vitro kinase assays were carried out using GST-c-Jun
protein as a substrate. Western blot analyses were performed using antibodies against FLAG (a-FLAG). The level of FLAG-p38 MAPK was
determined as the loading control. The input represents 10% of the total input immunoprecipitation. (C, D): SB203580 (10 lM), a p38 MAPK-
speciﬁc inhibitor, was pretreated for 1 hour before being treated with adiponectin (10 lg/ml) for 3 hours in C3H10T1/2 cells. (C): Western blot
analyses were conducted and antibodies against GAPDH (a-GAPDH) were used as the loading control. (D): Relative amounts of COX2 mRNA
were determined using real-time quantitative polymerase chain reaction (qPCR). Values are normalized to the levels of GAPDH mRNA. (E):
Cycloheximide (10 lM) and SB203580 (10 lM) were pretreated for 1 h. Adiponectin (10 lg/ml) was treated for 3 hours in C3H10T1/2 cells.
Relative amounts of COX2 mRNA were determined using real-time qPCR. Values are normalized to the levels of GAPDH mRNA. (F):
C3H10T1/2 cells were differentiated into osteoblasts for 5 days with or without adiponectin (10 lg/ml) and SB203580 (10 lM). Relative amounts
of COX2, osteopontin, and osteocalcin mRNA were determined using real-time qPCR. Values are normalized to the levels of GAPDH mRNA.
Values are expressed as the mean  SD. *, p < .05; **, p < .01. Abbreviations: APN, adiponectin; COX2, cyclooxygenase-2; CHX, cyclohexi-
mide; OCN, osteocalcin; OPN, osteopontin.
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in Figure 5B, NS398 evidently repressed an adiponectin-
dependent increase in BMP2 expression, indicating that
increased BMP2 expression by adiponectin is dependent on
COX2.
The ﬁnding that BMP2 activates Runx2 transcriptional
activity through R-Smads [31] and that adiponectin promotes
several Runx2 target genes, including osteocalcin and osteo-
pontin (Fig. 1), led us to examine the effect of adiponectin on
the transcriptional activity of Runx2. Adiponectin greatly aug-
mented the transcriptional activity of Runx2 on the osteocal-
cin promoter in the reporter assays (Fig. 5C), although the
underlying mechanism by which adiponectin stimulates
Runx2 activity is largely unknown. Adiponectin consistently
increased the recruitment of Runx2 and the coactivator p300
onto the promoter regions of osteocalcin and osteopontin,
which were determined by ChIP assays (Fig. 5D). Further-
more, suppression of BMP2 receptors, including BMPR1a,
BMPR1b, and Acvr1, inhibited the recruitment of Runx2 onto
the promoter regions of its target genes in the presence of adi-
ponectin (supporting information Fig. S7). This implied that
adiponectin could also stimulate the transcriptional activity of
Runx2 through BMP2 signaling in mesenchymal progenitor
cells.
Since COX2 has been reported as one of the direct targets
of Runx2 in osteoblasts [24, 32, 33], we investigated the
effect of Runx2 suppression on adiponectin-induced COX2
expression. As shown in Figure 5E, Runx2 knockdown
decreased the level of COX2 expression in the presence of
adiponectin. Although further studies are required to under-
stand how adiponectin is able to elevate Runx2 activity, these
observations indicate that Runx2 activated by adiponectin
could promote COX2 expression.
AdipoR1 Is the Major Functional Receptor for
Adiponectin Signaling in C3H10T1/2 Cells
Both AdipoR1 and R2 are expressed in mesenchymal progeni-
tor cells and osteoblasts [22, 34], and AdipoR1 appears to be
a major receptor for adiponectin in human primary osteoblasts
[16]. Although we detected both AdipoR1 and R2 mRNA in
mesenchymal progenitor cells and bone marrow regions
Figure 5. Adiponectin stimulates BMP2 expression and Runx2 tran-
scriptional activity. (A): Adiponectin (10 lg/ml) was treated for the
indicated time periods in C3H10T1/2 cells. Relative amounts of
BMP2 and BMP7 mRNA were determined using real-time quantita-
tive polymerase chain reaction (qPCR). Values are normalized to the
levels of GAPDH mRNA. (B): Adiponectin (10 lg/ml) and NS398
(20 lM) were added to C3H10T1/2 cells for 3 hours. Relative
amounts of mRNA were determined using real-time qPCR. Values
are normalized to the levels of GAPDH mRNA. (C): A reporter con-
struct containing the osteocalcin promoter was co-transfected with a
Myc-tagged Runx2 expression vector into HEK293 cells. Runx2 tran-
scriptional activity was determined with and without adiponectin
(10 lg/ml). Luciferase activities were determined 24 hours after trans-
fection. Transfection efﬁciency was normalized using b-gal activity.
(D): C3H10T1/2 cells were treated with adiponectin (10 lg/ml) for
3 hours. ChIP assays were performed to determine the recruitment of
Runx2 and coactivator p300 onto the promoter of osteocalcin and
osteopontin. The input represents 10% of the total input chromatin.
(E): C3H10T1/2 cells were transfected with scrambled or Runx2
siRNA and treated with and without adiponectin (10 lg/ml) for 3 hours.
Western blot analyses were conducted using antibodies against COX2
(a-COX2). Antibodies against b-actin (a-b-actin) were used as the
loading control. Values are expressed as the mean  SD. *, p < .05;
**, p < .01. Abbreviations: APN, adiponectin; COX2, cyclooxygen-
ase-2; CHX, cycloheximide; OCN, osteocalcin; OPN, osteopontin.
Figure 6. AdipoR1 is the major adiponectin receptor for osteoblast
differentiation. (A): The levels of AdipoR1 and R2 mRNA were
measured by real-time quantitative polymerase chain reaction (qPCR)
in the process of osteogenesis with C3H10T1/2 cells. Values are nor-
malized to the levels of 18S rRNA. (B–E): C3H10T1/2 cells were
transfected with scrambled or AdipoR1 siRNA. (B): AdipoR1 and R2
mRNA were measured by real-time qPCR. Values are normalized to
the levels of GAPDH mRNA. (C): Adiponectin (10 lg/ml) was
treated for the indicated time periods. The phosphorylation and pro-
tein levels of p38 MAPK were detected by Western blot analyses.
Antibodies against GAPDH (a-GAPDH) were used as the loading
control. (D): Adiponectin (10 lg/ml) was treated for 3 hours. COX2
mRNA was measured by real-time qPCR. Values are normalized to
the levels of GAPDH mRNA. (E): siRNA transfected C3H10T1/2
cells were differentiated for 5 days with and without adiponectin
(10 lg/ml) and relative amounts of COX2, osteopontin, and osteocal-
cin mRNA were determined using real-time qPCR. Values are nor-
malized to the levels of GAPDH mRNA. Pre-, undifferentiated
C3H10T1/2 cells, day 5, C3H10T1/2 cells were osteogenic differenti-
ated for day 5; si-con, scrambled si-RNA; si-AdipoR1, AdipoR1
si-RNA. Values are expressed as the mean  SD. *, p < .05; **, p <
.01. Abbreviations: APN, adiponectin; COX2, cyclooxygenase-2;
OCN, osteocalcin; OPN, osteopontin.
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(supporting information Fig. S8), the mRNA expression level
of AdipoR1 was greater than that of AdipoR2 in C3H10T1/2
cells, PBMCs, and MC3T3-E1 cells (Fig. 6A, supporting
information Fig. S9). In addition, AdipoR1 mRNA expression
was elevated during differentiation in mesenchymal progenitor
cells (Fig. 6A, supporting information Fig. S9). To investigate
whether adiponectin signaling is mediated by AdipoR1 during
osteogenesis, we speciﬁcally repressed AdipoR1 expression
(about 38%) using siRNA in C3H10T1/2 cells (Fig. 6B).
When the expression of AdipoR1 was suppressed, both p38
MAPK phosphorylation (Fig. 6C) and COX2 expression (Fig.
6D) by adiponectin were greatly decreased. Furthermore, adi-
ponectin-dependent increases of COX2, osteopontin, and
osteocalcin expression were reduced by AdipoR1 siRNA dur-
ing osteoblast differentiation (Fig. 6E). These results suggest
that AdipoR1 would play a key role in mediating adiponectin
signaling cascade for the regulation of osteoblast differentia-
tion in mesenchymal progenitor cells.
DISCUSSION
Certain cytokines that are secreted from adipocytes and osteo-
blasts reciprocally inﬂuence bone and fat metabolism [9, 35,
36]. However, there are some discrepancies regarding the role
of adiponectin in bone metabolism. Several reports suggest
that adiponectin enhances bone mineral density in vivo and
osteoblast differentiation in vitro [16, 37]. In contrast, serum
levels of adiponectin are inversely correlated with bone min-
eral density [38], and the bone mass of adiponectin-deﬁcient
mice is not signiﬁcantly different from that of wild-type mice
[34]. Although adiponectin mRNA was expressed in mesen-
chymal progenitor cells and osteoblasts, a signiﬁcantly abun-
dant level of adiponectin was detected in differentiated adipo-
cytes (supporting information Fig. S8). However, several
ﬁndings suggest that adiponectin has a paracrine role in bone
marrow and mesenchymal progenitor cells. For instance, the
adiponectin protein level in bone marrow ﬂuid is much higher
than that in serum, and 4-week-old mice have more abundant
levels of adiponectin in bone marrow ﬂuid than do 14-week-
old mice [22]. Regarding adipogenesis, adiponectin inhibits
adipocyte differentiation in mesenchymal progenitor cells in a
COX2-dependent manner [23]. We also observed that adipo-
nectin lessened adipogenesis in C3H10T1/2 cells (supporting
information Fig. S10). Interestingly, osteoblast differentiation
in bone marrow progenitor cells from adiponectin-deﬁcient
mice is signiﬁcantly repressed when compared to that of con-
trol mice [34]. Consistent with the above reports, we demon-
strated that treatment of adiponectin stimulated differentiation
of osteoblasts through COX2 induction in several mesenchy-
mal progenitor cells, including C3H10T1/2 cells and PBMCs.
In bone biology, COX2 is an important inducer of osteo-
blast differentiation [21]. However, we revealed the molecular
mechanism by which adiponectin-induced COX2 would stim-
ulate osteoblast differentiation. Previously, COX2 was
reported to regulate the expressions of BMPs, including
BMP2 and BMP7, in mesenchymal progenitor cells and osteo-
blasts [30, 39]. Because adiponectin increased BMP2 expres-
sion via COX2 induction (Fig. 5), it is likely that the increase
in BMP2 expression via COX2 by adiponectin would lead to
pleiotrophic increases in osteogenic marker gene expression.
We believe that this is the ﬁrst evidence that adiponectin
increases BMP2 expression, where COX2 is an important
mediator linking adiponectin and BMP2 expression in the pro-
cess of osteogenesis of mesenchymal progenitor cells.
Several reports have revealed that adiponectin is able to
modulate COX2 expression in PBMCs and cardiac myocytes
[23, 40]. Although COX2 induction by adiponectin in cardiac
myocytes is dependent on sphingosine kinase-1 [41], we have
shown that adiponectin serially activated AdipoR1, p38
MAPK, and the c-Jun signaling pathway to induce COX2
expression in mesenchymal progenitor cells. On the basis of
similar data, Luo et al. recently reported that adiponectin acti-
vates p38 MAPK via AdipoR1 in human osteoblasts. Unlike
p38 MAPK, AMPK was not involved in adiponectin-induced
COX2 expression or osteogenesis (supporting information
Fig. S11). Furthermore, we ﬁrst observed that adiponectin
stimulated c-Jun phosphorylation. Several lines of evidence
suggest that c-Jun is a key transcription factor in COX2
expression upon adiponectin in mesenchymal progenitor cells.
First, adiponectin markedly increased c-Jun expression and
elevated
c-Jun phosphorylation (Figs. 3B, 4A). Second, recruitment of
c-Jun and its cofactor, p300, onto the promoter of COX2 was
augmented by adiponectin (Fig. 3C). Third, knockdown of
c-Jun suppressed the increase in COX2 expression by adipo-
nectin (Fig. 3D). Together, it is feasible to propose that a
sequential signaling cascade (adiponectin ! AdipoR1 ! p38
MAPK ! c-Jun) is involved in inducing COX2 expression
upon adiponectin in mesenchymal progenitor cells.
During osteoblast differentiation, the expression and modi-
ﬁcation of Runx2, a key transcription factor in osteogenesis,
play crucial roles [42]. In the present study, we observed that
adiponectin promoted the transcriptional activity of Runx2
and Runx2 binding onto the promoter of target genes like
osteocalcin and osteopontin (Fig. 5). Moreover, COX2 expres-
sion by adiponectin was repressed by Runx2 knockdown
(Fig. 5E), suggesting that Runx2 would contribute to stimulat-
ing COX2 expression by adiponectin. However, in mesenchy-
mal progenitor cells, adiponectin did not change the levels of
Runx2 mRNA (Fig. 2A) and Runx2 phosphorylation, which
are associated with increased Runx2 transcriptional activity
(data not shown). This implies that adiponectin might indirectly
Figure 7. A model for adiponectin signaling to stimulate osteoblast
differentiation in mesenchymal progenitor cells. In mesenchymal pro-
genitor cells, adiponectin activates AdipoR1, p38 MAPK, and c-Jun
to increase the expression of COX2. The COX2 pathway is essential
for increasing BMP2 expression following adiponectin administration.
Activated BMP2 signaling might contribute to promoting osteoblast
differentiation through activation of Runx2 in mesenchymal progeni-
tor cells. Activated Runx2 by adiponectin would stimulate osteogenic
marker genes expression and COX2 expression to enhance osteogene-
sis. Prostaglandin E (EP) receptors; PGE2 receptors. Abbreviations:
COX2, cyclooxygenase-2; PGE2, prostaglandin E2; Runx2, Runt-
related transcription factor 2.
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regulate Runx2 activity through another pathway. Neverthe-
less, it is of interest to note that the suppression of BMP2
signaling repressed Runx2 recruitment onto its target gene
promoters (supporting information Fig. S7). It is possible to
explain these observations by the following model in which
adiponectin-induced BMP2 signaling might prompt Runx2
transcriptional activity through activation of Smads (Fig. 7).
Further studies are required to understand the effect of acti-
vated BMP2 expression by adiponectin on transcriptional
activity of Runx2 in mesenchymal progenitor cells.
Collectively, it is possible to suggest that adiponectin acti-
vates the AdipoR1 ! p38 MAPK ! c-Jun cascade to pro-
mote COX2 expression in mesenchymal progenitor cells and
that activated COX2 would increase BMP2 expression and
stimulate osteoblast differentiation (Fig. 7). Although further
in vivo studies should test whether adiponectin is capable of
inducing bone formation in the bone marrow region, the data
presented here suggest that adiponectin could be a potent ther-
apeutic agent for diseases with diminished bone regions by
activating osteoblast differentiation in mesenchymal progeni-
tor cells.
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